Search results
Results from the WOW.Com Content Network
Emergent BioSolutions (NYSE: EBS) Q2 2024 Earnings Call Aug 06, ... In addition to today's press release, there is a series of slides accompanying this webcast available to all webcast ...
Emergent BioSolutions (NYSE: EBS) Q3 2024 Earnings Call Nov 06, ... In addition to today's press release, a slide presentation accompanying this webcast is available to all webcast participants ...
In May, Emergent cut about 300 jobs and shut down a drug substance manufacturing facility in Baltimore, Bayview and a drug product facility in Rockville, Maryland. Emergent to cut up to 70 roles ...
(Reuters) -The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions' smallpox vaccine for use in people at high risk of mpox infection. The FDA clearance, announced ...
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for ...
On June 1, 2006, the DHHS awarded a $363 million contract to Emergent BioSolutions, (then Cangene Corporation) for 200,000 doses of BAT over five years for delivery into the US Strategic National Stockpile (SNS). [10] The CDC began supplying doses to the SNS in 2007 under a now $427 million contract with the DHHS, according to a Cangene press ...
Emergent's ACAM2000 vaccine, approved for smallpox, has been used as an mpox shot but the U.S. Food and Drug Administration is yet to approve its application for u Emergent to donate 50,000 ...